Market Research Logo

Global Botanical & Plant Derived Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 – 2023

Global Botanical & Plant Derived Drug Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 – 2023

Botanical and plant derived drug market is rising with increasing prevalence of chronic diseases. According to National Institute of Health one in every five US citizen is currently living with some form of cardiovascular disease or stroke in 2016. Both cardiovascular disease and stroke brought a $350 billion burden to US economy in 2015. The burden on economy due to these disease is anticipated to increase by 5% annually. Cancer is the next most prevalent non-communicable chronic disease (NCDs) in US. National Cancer Institute estimates over 19 million people in US to be affected with some form of cancer by 2024 which has increased from 15 million in 2015. Breast cancer, lung cancer, stomach cancer, and bronchus cancer are amongst the leading forms of cancer affecting North American population. Similarly, over 86% of the total deaths in Europe resulted from NCD’s according to WHO. Prevalence rate of diabetes, cancer and cardiovascular diseases are higher amongst the Western Europe and Southern European population. Europe has currently over 12% of its total population aged 60 years and above. By 2025 over 18% of European will be aged 60 years and above. With aging population prevalence rate of NCDs will increase. In next five years, prevalence rate of obesity in regions like Asia Pacific, Africa and Latin America will increase by 3% YoY. According to Asia Journal of Cancer Prevention the number of people living with cancer is estimated to reach over 15 million by 2019. Lung cancer, breast cancer, thyroid cancer, and prostate cancer are the common forms of cancer commonly found among Asia Pacific population. Along with cancer, the prevalence rate of diabetes in Asia Pacific is estimated to increase by 7% per annum. Above development endorses the growth of botanical and plant derived drug market growth from $25,400 million in 2016 to $41,722 million by 2023. The market is anticipated to grow at CAGR 6.2% during period 2016-2023.

Some of the other factors driving market include, technological advancement in drug production procedure, increasing use of plant derived drugs, and low price compared to other forms of drugs. Stringent laws and regulations, low acceptance rate for infectious diseases, lack of awareness about botanical drugs, and availability of alternative substitute are the factors impact the market growth for the forecast period 2016-2023.

Region wise global botanical and plant derived market is segmented into North America, Asia Pacific, Europe and Rest of the World (ROW). North America and Europe dominates the market in terms of revenue. Increasing awareness about botanical drugs, presence of companies manufacturing drugs from plants, sound regulatory environment and increasing prevalence rate of NCD’s are the prime factors aiding market growth in North America and Europe. Asia Pacific is the fastest growing market for the forecasted period. Japan, India and China are leading market growth in Asia Pacific. Increasing healthcare expenditure, aging population, increasing prevalence of chronic diseases are the factors driving growth of botanical and plant derived drug market in Asia Pacific.

Abbott Laboratories Ltd., Bayer Healthcare Ltd., Bionova Inc., Bristol Meyers Ltd., Eli Lilly Ltd., and GSK Ltd., are amongst the pioneers in botanical and plant derived drug market. Collaborations with regional institutions, and M&A are amongst the strategies adopted by companies to grow their market share.
Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. MARKET SCOPE
2. MARKET OVERVIEW
2.1. GLOBAL BOTANICAL & PLANT DERIVED MARKET: EVOLUTION & TRANSITION
2.2. INDUSTRY STRUCTURE
2.3. REGULATORY FRAMEWORK
2.4. TOTAL MARKET ANALYSIS
2.4.1. TOP FINDINGS
2.4.2. TOP OPPORTUNITY MARKETS
2.4.3. TOP COMPANIES
2.4.4. TOP COMPETITIVE STRATEGIES
2.5. ESTIMATION ANALYSIS
2.6. STRATEGIC ANALYSIS
2.6.1. INVESTMENT VS. ADOPTION MODEL
2.6.2. 360 DEGREE INDUSTRY ANALYSIS
2.6.3. PORTERS 5 FORCE MODEL
2.6.4. SEE-SAW ANALYSIS
2.6.5. PRICING ANALYSIS
2.6.6. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.6.7. ROI ANALYSIS
2.6.8. GAP ANALYSIS
2.7. COMPETITIVE ANALYSIS
2.7.1. KEY STRATEGIES AND ANALYSIS
2.7.2. MARKET SHARE
2.7.3. TOP COMPANY ANALYSIS
2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS& MARKET IMPACT
3.1.1. INCREASING PREVALENCE OF CHRONIC DISEASES
3.1.2. TECHNOLOGICAL ADVANCEMENT IN PRODUCTION PROCEDURE
3.1.3. COMPARATIVELY LOW PRICE
3.1.4. INCREASE IN USE OF PLANT DERIVED DRUGS
3.2. MARKET RESTRAINTS & MARKET IMPACT
3.2.1. STRINGENT GOVERNMENT LAWS & REGULATIONS
3.2.2. LOW ACCEPTANCE RATE FOR LETHAL DISEASES
3.3. MARKET OPPORTUNITIES
3.3.1. ENHANCED APPLICATIONS
3.3.2. INCREASING APPROVAL BY FDA
3.4. MARKET CHALLENGES
3.4.1. LACK OF AWARENESS ABOUT BOTANICAL DRUGS
3.4.2. AVAILABILITY OF ALTERNATIVE SUBSTITUTES
4. MARKET SEGMENTATION
4.1. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY DRUG TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. STEROIDS
4.1.5.1.1. APPLICATIONS
4.1.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.1.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.5. KEY CONCLUSIONS
4.1.5.2. PHENOLS
4.1.5.2.1. APPLICATIONS
4.1.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.1.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.5. KEY CONCLUSIONS
4.1.5.3. TERPENES
4.1.5.3.1. APPLICATIONS
4.1.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.1.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.3.5. KEY CONCLUSIONS
4.1.5.4. GLYCOSIDES
4.1.5.4.1. APPLICATIONS
4.1.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
4.1.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.1.5.4.5. KEY CONCLUSIONS
4.2. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY APPLICATION
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. HORMONE DISEASES
4.2.5.1.1. APPLICATIONS
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. RESPIRATORY & ONCOLOGY DISEASE
4.2.5.2.1. APPLICATIONS
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5. KEY CONCLUSIONS
4.2.5.3. INFECTIOUS DISEASE
4.2.5.3.1. APPLICATIONS
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.5. KEY CONCLUSIONS
4.2.5.4. CARDIOVASCULAR & METABOLIC DISEASE
4.2.5.4.1. APPLICATIONS
4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.5. KEY CONCLUSIONS
4.2.5.5. PAIN & CNS DISORDER
4.2.5.5.1. APPLICATIONS
4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.5. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF M&A
5.1.2. LIST OF JV
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIP
5.2. TOP 10 COMPANY ANALYSIS – DASHBOARD
6. GLOBAL BOTANICAL & PLANT DERIVED MARKET BY REGION
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GEOGRAPHIC SEGMENTATION
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY APPLICATION ANALYSIS
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY APPLICATION ANALYSIS
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. ITALY
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.2.2.6. REST OF EUROPE
6.4.2.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.6.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.6.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY APPLICATION ANALYSIS
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. SOUTH KOREA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. AUSTRALIA
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.3.2.6. REST OF ASIA PACIFIC
6.4.3.2.6.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.6.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.6.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY APPLICATION ANALYSIS
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.2. BAYER HEALTHCARE
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.3. BIONOVA
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.4. BRISTOL MEYERS
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.5. ELI LILLY
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.6. GSK LTD
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.7. JHONSON & JHONSON
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.8. LUPIN LTD
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.9. MEDIGENE
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.10. NOVARTIS INTERNATIONAL
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.11. PFIZER
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.12. RANBAXY LABS
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.13. GLENMARK PHARMACEUTICALS LTD
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.14. TASLY PHARMACEUTICALS INC
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.15. PIRAMAL PHYTOCARE LTD
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
LIST OF TABLES
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY DRUG TYPE 2014-2023 ($ MILLION)
GLOBAL STEROID DRUG TYPE BOTANICAL & PLANT DERIVED MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PHENOL DRUG TYPE BOTANICAL & PLANT DERIVED MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL TERPENES DRUG TYPE MARKET BY PRODUCT 2014-2023 ($ MILLION)
GLOBAL GLYCOSIDES DRUG TYPE MARKET BY PRODUCT 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY APPLICATION 2014-2023 ($ MILLION)
GLOBAL HORMONE DISEASE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
GLOBAL PAIN & CNS DISORDER BY GEOGRAPHY 2014-2023 ($ MILLION)
NORTH AMERICA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
EUROPE BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
ASIA PACIFIC BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
REST OF THE WORLD BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
LIST OF FIGURES
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY STEROID DRUG TYPE 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY PHENOL DRUG TYPE 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY TERPENES DRUG TYPE 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY GLYCOSIDE DRUG TYPE 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY SOFT-TUBE FILLING AND SEALING MACHINES 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY HORMONE DISORDER 2014-2023 ($ MILLION)
GLOBAL BOTANICAL & PLANT DERIVED MARKET BY PAIN & CNS DISORDER 2014-2023 ($ MILLION)
UNITED STATES (U.S.) BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
CANADA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
UNITED KINGDOM (UK) BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
FRANCE BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
GERMANY BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
SPAIN BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
ITALY BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
ROE BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
INDIA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
CHINA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
JAPAN BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
KOREA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
AUSTRALIA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
ROW APAC BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
LATIN AMERICA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)
MENA BOTANICAL & PLANT DERIVED MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report